Skip to Content


In the US, Eltrombopag (eltrombopag systemic) is a member of the drug class platelet-stimulating agents and is used to treat Aplastic Anemia, Idiopathic Thrombocytopenic Purpura, Thrombocytopenia and Thrombocytopenia Idiopathic.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Hematopoietic growth factor: Stimulation of thrombopoiesis

Hemostatic agent: Treatment of thrombocytopenia

Thrombopoietin receptor agonist

Chemical Names

(Z)-3'-{N'-[1-(3,4-Dimetylphenyl)-3-metyl-5-oxo-1,5-dihydropyrazolyliden]hydrazin}-2'-hydroxybiphenyl-3-carbonsäure (IUPAC)

[1,1'-Biphenyl]-3-carboxylic acid, 3'-[(2Z)-[1-(3,4-dimetylphenyl)-1,5-dihydro-3-metyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-

3'-{(2Z)-2-[1-(3,4-dimetylphenyl)-3-metyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]diazanyl}-2'-hydroxybiphenyl-3-carboxylic acid (WHO)

Foreign Names

  • Eltrombopagum (Latin)
  • Eltrombopag (German)
  • Eltrombopag (French)
  • Eltrombopag (Spanish)

Generic Names

  • SB 497115 (IS)
  • UNII-S56D65XJ9G (IS)
  • Eltrombopag Olamine (OS: USAN, JAN)
  • SB-497115-GR (IS)
  • UNII-4U07F515LG (IS)

Brand Names

  • Eltrombopag
    Hetero, United States
  • Revolade
    Glaxo Smithkline, Lebanon; Glaxo Wellcome, Serbia; GlaxoSmithKline, Cyprus; GlaxoSmithKline, Poland; GSK, Peru; Novartis, Bosnia & Herzegowina; Novartis, Brazil; Novartis, Lithuania; Novartis, Turkey; Novartis Europharm, Slovenia; Novartis Europharm, Tunisia; Novartis Europharm Limited, Latvia
  • Revolade 50 mg
    Novartis, Hungary
  • Promacta
    Novartis, United States
  • Rebozet
    GlaxoSmithKline, Indonesia
  • Revolade
    Glaxo Operations UK, Macedonia; GlaxoSmithKline, Chile; GlaxoSmithKline, Croatia (Hrvatska); GlaxoSmithKline, Malaysia; GlaxoSmithKline, Philippines; GlaxoSmithKline, Singapore; GlaxoSmithKline, Thailand; GlaxoWellcome, Georgia; Novartis, Argentina; Novartis, Belgium; Novartis, Czech Republic; Novartis, Denmark; Novartis, Estonia; Novartis, Finland; Novartis, France; Novartis, Hong Kong; Novartis, Ireland; Novartis, Japan; Novartis, Norway; Novartis, New Zealand; Novartis, Portugal; Novartis, Sweden; Novartis, Slovakia; Novartis Europharm, Greece; Novartis Europharm, Romania; Novartis Europharm Limited, Iceland; Novartis Europharm Limited, Netherlands; Novartis Farmaceutica, Spain; Novartis Pharmaceuticals, Australia; Novartis Pharmaceuticals, Canada; Novartis Pharmaceuticals UK, United Kingdom
  • Revolade 25 mg
    Novartis, Hungary
  • Revolade 25mg
    Glaxo Wellcome, Israel; Novartis, Luxembourg; Novartis Europharm, Austria; Novartis Pharma, Switzerland; Novartis Pharma, Germany; GlaxoSmithKline GSK, Oman
  • Revolade 50mg
    Glaxo Wellcome, Israel; Novartis, Luxembourg; Novartis Europharm, Austria; Novartis Pharma, Switzerland; Novartis Pharma, Germany; GlaxoSmithKline GSK, Oman
  • Revolade 75mg
    Novartis Europharm, Austria; Novartis Pharma, Germany


IUPACInternational Union of Pure and Applied Chemistry
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.